我们报告遵守英国关于芬戈莫德相关性黄斑水肿（FAME）监测的国家指南，以及对我们单位临床服务的影响。我们进行了为期9个月的研究,测量推荐间隔，对进行FAME监测的所有患者进行视觉功能和OCT扫描。共见到38例患者，占研究期间所有新眼科转诊的9%。26％的患者在开始芬戈莫德治疗后2至4个月之间，74%在开始芬戈莫德治疗后3至4个月之间。讨论了对临床服务的影响。
We report adherence to United Kingdom national
guidelines on surveillance for Fingolimod associated macular oedema (FAME) and the impact on clinical services at our unit. We conducted a 9-month study, measuring referral interval, visual function and performing OCT scans for all patients referred for FAME surveillance. 38 patients in total were seen, representing 9% of all new ophthalmic referrals during the study period. 26% were seen between 2 and 4 months after starting Fingolimod treatment, 74% between 3 and 4 months after starting Fingolimod treatment. The impact on clinical services is discussed.
